Need for Ethical Governance on the Implementation and Use of Patient-derived Xenograft (PDX) Models for Anti-cancer Drug Discovery and Development: Ethical Considerations and Policy Proposal
Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors...
Saved in:
Published in | JMA Journal Vol. 7; no. 4; pp. 605 - 609 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Japan
Japan Medical Association / The Japanese Associaiton of Medical Sciences
15.10.2024
Japan Medical Association |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the custodianship model as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research. |
---|---|
AbstractList | Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the
custodianship model
as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research. Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the custodianship model as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research.Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the custodianship model as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research. Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research. Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the custodianship model as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research. |
Author | Hamada, Akinobu Yagishita, Shigehiro Matsui, Kenji |
Author_xml | – sequence: 1 fullname: Yagishita, Shigehiro organization: Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan – sequence: 1 fullname: Matsui, Kenji organization: Division of Bioethics and Healthcare Law, National Cancer Center Institute for Cancer Control, Tokyo, Japan – sequence: 1 fullname: Hamada, Akinobu organization: Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39513080$$D View this record in MEDLINE/PubMed |
BookMark | eNpVUk1v1DAUjFARLaVnbsjHckjrjyQ4CAlVu22pVGAPVNqb5Tgvu145drC9K-2f47fh7LYRHCxb8-bNPPnN2-zEOgtZ9p7gK0aqil5verm5opiyHJO6fpWd0YKxnNGan0xvvjzNLkLYYIxpTSnn5E12yuqSMMzxWfbnB0CLOufRbVxrJQ26dzvwVloFyFkU14Ae-sFADzbKqBMkbYueQqp2aJGQhOcteL1LOkuwbuVlF9HlYr78iL67Fkw4yN_YqHM1yno099sVmuugRqv9QXAOOzBuGF0-T6PMnA06aR98w4G3cEarPVp4N7ggzbvsdSdNgIvn-zx7urv9NfuWP_68f5jdPOaqKIuY85pB3eGOlVWDVdXwDuOGMuhkyyQvGgbAK1ynV4uBlA1uyppjWjUtV5y0ip1nX4-6w7bpoVVpTC-NGLzupd8LJ7X4v2L1WqzcThBSpj2wIilcPit493sLIYo-fQAYIy24bRCMUM4ow4Qn6od_zSaXl60lwvWRoLwLwUM3UQgWh2iIMRpijIYYo5E6vhw7NiHKFUx86aNWBo70T6JIp8LlBKu19AIs-wszD8Z3 |
ContentType | Journal Article |
Copyright | 2024 Japan Medical Association Copyright © Japan Medical Association. Copyright © Japan Medical Association |
Copyright_xml | – notice: 2024 Japan Medical Association – notice: Copyright © Japan Medical Association. – notice: Copyright © Japan Medical Association |
DBID | AAYXX CITATION NPM 7X8 5PM |
DOI | 10.31662/jmaj.2023-0199 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2433-3298 |
EndPage | 609 |
ExternalDocumentID | PMC11543334 39513080 10_31662_jmaj_2023_0199 article_jmaj_7_4_7_605_article_char_en |
Genre | Journal Article |
GroupedDBID | ALMA_UNASSIGNED_HOLDINGS JSF JSH OK1 PGMZT RJT RPM RZJ AAYXX CITATION NPM 7X8 5PM |
ID | FETCH-LOGICAL-c454t-893e9f0f356b0c6b8f00b23efad3a84b3ee860984bd0e15b0b598026bd8c81dc3 |
ISSN | 2433-328X 2433-3298 |
IngestDate | Thu Aug 21 18:30:06 EDT 2025 Thu Jul 10 22:06:27 EDT 2025 Mon Jul 21 06:07:19 EDT 2025 Tue Jul 01 02:28:49 EDT 2025 Wed Sep 03 06:30:48 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | trust patient-derived xenograft model research ethics ethical governance policy |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Copyright © Japan Medical Association. JMA Journal is an Open Access journal distributed under the Creative Commons Attribution 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c454t-893e9f0f356b0c6b8f00b23efad3a84b3ee860984bd0e15b0b598026bd8c81dc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Corresponding author: Kenji Matsui, kematsui@ncc.go.jp |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC11543334 |
PMID | 39513080 |
PQID | 3128323018 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11543334 proquest_miscellaneous_3128323018 pubmed_primary_39513080 crossref_primary_10_31662_jmaj_2023_0199 jstage_primary_article_jmaj_7_4_7_605_article_char_en |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-10-15 |
PublicationDateYYYYMMDD | 2024-10-15 |
PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan |
PublicationTitle | JMA Journal |
PublicationTitleAlternate | JMA J |
PublicationYear | 2024 |
Publisher | Japan Medical Association / The Japanese Associaiton of Medical Sciences Japan Medical Association |
Publisher_xml | – name: Japan Medical Association / The Japanese Associaiton of Medical Sciences – name: Japan Medical Association |
References | 5. Toya W, Yamamoto K, Aizawa K, et al. Paid-for transfer of human samples in research biobanks and the applicability of charitable trusts. Jpn J Clin Pharmacol Ther. 2022;54 (1):29-36. Japanese. 1. Gamo NJ, Birknow MR, Sullivan D, et al. Valley of death: a proposal to build a "translational bridge" for the next generation. Neurosci Res. 2017;115:1-4. 4. Yassin R, Lockhart N, del Riego MG, et al. Custodianship as an ethical framework for biospecimen-based research. Cancer Epidemiol Biomarkers Prev. 2010;19 (4):1012-5. 3. Ledford H. US cancer institute overhauls cell lines. Nature. 2016;530 (7591):391. 2. Liu Y, Wu W, Cai C, et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8 (1):160. |
References_xml | – reference: 3. Ledford H. US cancer institute overhauls cell lines. Nature. 2016;530 (7591):391. – reference: 5. Toya W, Yamamoto K, Aizawa K, et al. Paid-for transfer of human samples in research biobanks and the applicability of charitable trusts. Jpn J Clin Pharmacol Ther. 2022;54 (1):29-36. Japanese. – reference: 4. Yassin R, Lockhart N, del Riego MG, et al. Custodianship as an ethical framework for biospecimen-based research. Cancer Epidemiol Biomarkers Prev. 2010;19 (4):1012-5. – reference: 1. Gamo NJ, Birknow MR, Sullivan D, et al. Valley of death: a proposal to build a "translational bridge" for the next generation. Neurosci Res. 2017;115:1-4. – reference: 2. Liu Y, Wu W, Cai C, et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8 (1):160. |
SSID | ssj0002922881 |
Score | 2.2780764 |
Snippet | Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently... |
SourceID | pubmedcentral proquest pubmed crossref jstage |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 605 |
SubjectTerms | ethical governance policy Opinion patient-derived xenograft model research ethics trust |
Title | Need for Ethical Governance on the Implementation and Use of Patient-derived Xenograft (PDX) Models for Anti-cancer Drug Discovery and Development: Ethical Considerations and Policy Proposal |
URI | https://www.jstage.jst.go.jp/article/jmaj/7/4/7_605/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/39513080 https://www.proquest.com/docview/3128323018 https://pubmed.ncbi.nlm.nih.gov/PMC11543334 |
Volume | 7 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | JMA Journal, 2024/10/15, Vol.7(4), pp.605-609 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKQIgXxJ1wk5F4GJqypbGTJrxNG2hC6lSJVepbFCdOm8KSqW2Q4MfxI_hFnGMnrlP2AHtoVLmu7eR88bn4XAh5B89dZiwbuiJkhct9UbhxIJgbs5Tl2QgE5hwDhcfn4dmUf54Fs8Hgt-W11GzEYfbz2riSm1AV2oCuGCX7H5Q1g0IDfAf6whUoDNd_ovE5sB7lJ6i81uFh68q5KgpAHwLo7L-XbYCRdjyeavP9RGdUdXNY6XcYZyYrdNXSBXompzO0F2CltG8qYwNmGSjdDIdeHZyumjnm7cxwuh-tN7NxPkIjQ7egrh5o63CnQhNUJmKMULiq1-0ddtLx-PjAvnFlKd-sm7KNIFqWZpNK52g806Lvl0U5l4tyVVvm-DTXBuOvZVWLxrZt-ByZgo7u1HwH5IXtidUuXtUm6XPGXOar8sTAz-w2Xd262-VHFpi5tWOHXmAx_1DlaviLr7BhGGKi2uVlujzEgvMuSMbxloUax8bJ-ATzGzHG-C1y2wfVxbcsSCgd-LHvR6p2rlm6zjil5jjqz9ATlu4sQV-Yy-tUoV2PXktEunhA7re6DT3WQH1IBrJ6RO6OW--Nx-QX4pUCmGgLD7rFK60rCnilfbxSAAwFvNK6oDt4pQavdB_Q-p5qrKrhLaxSxCo1WFUDWlj9YJbSR6rqp5FKO6Q-IdNPHy9Ozty2foib8YBvXBDFZVx4BQtC4WWhiArPEz6TRZqzNOKCSRkBweFb7slhIDwRxJHnhyKPMlDjMvaU7FV1JZ8TygoGgjHmRWAFz1IpUjy_HI7kiIN0FzCH7HeESq50mpgE1GtF0wRpmiBNE6SpQwJNSNOx3T90v1HC4QOoNM0Yfgm7nUPednRPgAXguV5aybpZwyxYbww4deSQZxoHZmwGGhQDrdAhUQ8hpgOml-__UpULlWa-A_KLm__1Jbm3fa1fkb3NqpGvQYjfiDfqrfgDuen-GQ |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Need+for+Ethical+Governance+on+the+Implementation+and+Use+of+Patient-derived+Xenograft+%28PDX%29+Models+for+Anti-cancer+Drug+Discovery+and+Development%3A+Ethical+Considerations+and+Policy+Proposal&rft.jtitle=JMA+journal&rft.au=Matsui%2C+Kenji&rft.au=Yagishita%2C+Shigehiro&rft.au=Hamada%2C+Akinobu&rft.date=2024-10-15&rft.pub=Japan+Medical+Association&rft.issn=2433-328X&rft.eissn=2433-3298&rft.volume=7&rft.issue=4&rft.spage=605&rft.epage=609&rft_id=info:doi/10.31662%2Fjmaj.2023-0199&rft.externalDocID=PMC11543334 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2433-328X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2433-328X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2433-328X&client=summon |